United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $499.03, for a total transaction of $4,740,785.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company's stock, valued at $161,906,790.29. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
United Therapeutics Trading Up 1.8%
NASDAQ UTHR opened at $506.82 on Thursday. The firm's fifty day moving average price is $523.12 and its two-hundred day moving average price is $540.39. The firm has a market capitalization of $21.74 billion, a P/E ratio of 18.13, a price-to-earnings-growth ratio of 2.49 and a beta of 0.56. United Therapeutics Corporation has a 1 year low of $395.00 and a 1 year high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the business posted $6.41 earnings per share. On average, research analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.
Key Headlines Impacting United Therapeutics
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: United Therapeutics entered a $477.6 million accelerated share repurchase agreement, representing the remainder of its previously authorized $2.0 billion buyback. The program should reduce shares outstanding and increase remaining shareholders’ ownership and per-share earnings. United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
- Positive Sentiment: Analyst sentiment remains favorable, with 11 Buy ratings and two Holds and a reported average price target of $646, well above the stock’s recent trading level. This supports the view that UTHR’s pulmonary arterial hypertension franchise and pipeline retain meaningful value.
- Neutral Sentiment: Management presented at the Cantor Fitzgerald Global Healthcare Conference and the Wells Fargo Healthcare Conference. The supplied reports do not identify a major new announcement, guidance change, or clinical update, so the presentations appear unlikely to create a significant near-term catalyst. Cantor Fitzgerald Global Healthcare Conference Transcript
- Negative Sentiment: CEO Martine Rothblatt disclosed sales of 9,500 UTHR shares for approximately $4.74 million at an average price of $499.03. A separate report describes another 9,500-share sale for about $4.65 million at $489.20. Each transaction reduced her direct ownership by 2.84%; while such sales may be personal or scheduled, repeated insider selling can weigh on sentiment. United Therapeutics Executive Share Sale
- Negative Sentiment: The latest quarterly results were mixed: earnings per share exceeded estimates, but revenue of $783.3 million missed expectations of $804.65 million and declined 1.9% year over year. The stock also remains below its 50-day and 200-day moving averages, indicating continued technical pressure.
Analyst Ratings Changes
A number of analysts have weighed in on UTHR shares. Weiss Ratings cut shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, August 27th. Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday, August 6th. Finally, Bank of America cut their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $646.00.
View Our Latest Research Report on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
Several institutional investors have recently made changes to their positions in the stock. Callan Family Office LLC bought a new position in United Therapeutics in the second quarter valued at about $1,217,000. Leuthold Group LLC raised its holdings in United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company's stock worth $5,200,000 after purchasing an additional 3,126 shares during the period. Nicholas Investment Partners LP lifted its position in United Therapeutics by 478.5% during the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company's stock valued at $2,218,000 after purchasing an additional 3,766 shares in the last quarter. Havemeyer Place LP purchased a new position in United Therapeutics during the fourth quarter valued at $2,189,000. Finally, Seven Fleet Capital Management LP bought a new stake in United Therapeutics during the fourth quarter valued at about $633,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.
United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
